EUVIMEDEUVIMED entdecken
Übersichtsarbeit

For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy

Jordyn Silverstein, Neha Goyal, Katy K Tsai

Current Oncology Reports · 2024

DOI: 10.1007/s11912-024-01541-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2024. Verfasst von Jordyn Silverstein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles (UCLA), 757 Westwood Plaza, Los Angeles, CA, 90095, US…. Hauptthemen laut MEDLINE: Melanoma, Cancer Survivors, Quality of Life. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: This review summarizes the latest advancements in survivorship care for patients with advanced melanoma who received systemic therapy and emphasizes the areas where more research is needed. RECENT FINDINGS: Over the last decade there have been remarkable advances in the treatment of advanced and metastatic melanoma. Due to these novel treatments, including several immune checkpoint inhibitors and tyrosine kinase inhibitors, there are and will continue to be increasing numbers of long-term melanoma survivors who have been treated with systemic therapy. These patients will navigate new challenges are they are essentially among the first long term survivors after these novel therapies. Survivorship care focuses on improving the health-related quality of life of patients including the physical, emotional, social and functional effects of cancer that begin at diagnosis and continue through the end of life. Survivorship also includes screening for cancer recurrence and second cancers. As the number of melanoma survivors who received systemic therapy continues to grow, the survivorship care plan will become increasingly important for optimal care of patients even after their cancer treatments. Understanding the many domains of survivorship care for this group of patients is imperative for their care now and to identify unmet needs for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaCancer SurvivorsQuality of LifeHumansImmune Checkpoint InhibitorsSurvivorship

Stichwörter der Autor:innen

Melanoma survivorship quality of life

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles (UCLA), 757 Westwood Plaza, Los Angeles, CA, 90095, USA. JSilverstein@mednet.ucla.edu.
  • Department of Psycho-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA.
  • Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco (UCSF), San Francisco, CA, USA.

Zitieren

APA

Silverstein, J., Goyal, N., & Tsai, K. K. (2024). For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy. Current Oncology Reports. https://doi.org/10.1007/s11912-024-01541-6

Vancouver

Silverstein J, Goyal N, Tsai KK. For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy. Current Oncology Reports. 2024. doi:10.1007/s11912-024-01541-6

BibTeX
@article{Silverstein2024,
  author = {Silverstein, Jordyn and Goyal, Neha and Tsai, Katy K},
  title = {For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy},
  journal = {Current Oncology Reports},
  year = {2024},
  doi = {10.1007/s11912-024-01541-6}
}
Kostenlos starten →